Nexavar is the sort of competition that biotech investors have nightmares about. The market can't ignore this threat for much longer, and a share price of $2 isn't out of the question.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
